45.79
price up icon8.76%   3.69
pre-market  Vorhandelsmarkt:  45.95   0.16   +0.35%
loading

Guardant Health Inc Aktie (GH) Neueste Nachrichten

pulisher
Jun 03, 2025

ARK Investment Acquires 173K Shares of Guardant Health (GH) | GH Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Stock Surges on FDA Breakthrough Designation - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Why Guardant Health Stock Surged Nearly 9% Higher Today - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday? - Benzinga

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

Epigenetics Market Anticipated to Achieve 11.8% CAGR - GlobeNewswire Inc.

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health shares rise following FDA breakthrough designation By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health shares rise following FDA breakthrough designation - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Gains as FDA Grants Breakthrough Designation - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health gets FDA breakthrough device status for cancer detection test - Seeking Alpha

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health's Shield Multi-Cancer Test Receives FDA Breakthrough Device Designation - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health’s cancer test earns FDA breakthrough status - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Receives FDA Breakthrough Designation for Cancer Detection Test | GH Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

FDA Grants Breakthrough Device Designation to Guardant Health's - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Groundbreaking FDA Decision: Guardant's Blood Test Can Detect 8 Cancers With 98% Accuracy - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test - The Joplin Globe

Jun 03, 2025
pulisher
Jun 02, 2025

ARK Investment Acquires 158.7K Shares of Guardant Health (GH) | GH Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Cathie Wood’s ARK buys Guardant Health, sells Adaptive Biotechnologies stock - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients - MSN

Jun 02, 2025
pulisher
Jun 02, 2025

Raymond James reaffirms Guardant Health stock rating after NCCN update By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

Raymond James reaffirms Guardant Health stock rating after NCCN update - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Guardant Health (GH) Gains NCCN Approval for Colorectal Cancer Test | GH Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Guardant Health Announced the results of the Serena-6 Phase III Trial - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening | GH Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Liquid Biopsy Market for Cancer Detection, cfDNA & CTC Analysis | - openPR.com

Jun 02, 2025
pulisher
Jun 01, 2025

Guardant Health (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News - GuruFocus

Jun 01, 2025
pulisher
May 31, 2025

In Largest Molecular Residual Disease (MRD) Study in Colon Cance - GuruFocus

May 31, 2025
pulisher
May 31, 2025

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions - Yahoo Finance

May 31, 2025
pulisher
May 30, 2025

Guardant Health Inc (GH) Stock Price Up 5.11% on May 30 - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Upcoming Chicago Meeting for Guardant Health (GH) Investors | GH Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

How Delfi Therapeutics plans to make liquid biopsies more accessible - The Business Journals

May 30, 2025
pulisher
May 28, 2025

Guardant Health Inc (GH) Trading Down 3.27% on May 28 - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Nuveen Asset Management LLC - Defense World

May 28, 2025
pulisher
May 28, 2025

Guardant Health enhances cancer blood test capabilities By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 28, 2025

Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

Guardant Health enhances cancer blood test capabilities - Investing.com Australia

May 27, 2025
pulisher
May 27, 2025

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test | GH Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test - Eagle-Tribune

May 27, 2025
pulisher
May 25, 2025

Ameriprise Financial Inc. Purchases 76,124 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World

May 25, 2025
pulisher
May 23, 2025

New Tests Promise to Reveal the Secrets in Your Blood - WSJ

May 23, 2025
pulisher
May 23, 2025

Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca

May 23, 2025
pulisher
May 23, 2025

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting - BioSpace

May 23, 2025
pulisher
May 22, 2025

(GH) Technical Data - news.stocktradersdaily.com

May 22, 2025
pulisher
May 22, 2025

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting | GH Stock News - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know - Yahoo Finance

May 21, 2025
diagnostics_research DGX
$173.59
price down icon 0.46%
diagnostics_research WAT
$349.39
price up icon 1.66%
diagnostics_research LH
$250.51
price up icon 1.07%
$160.15
price down icon 0.34%
diagnostics_research MTD
$1,166.46
price up icon 2.22%
diagnostics_research IQV
$142.78
price up icon 2.65%
Kapitalisierung:     |  Volumen (24h):